思瑞康与维思通治疗精神分裂症的对照研究  

Comparison of efficacy and safety of Seroquel and Resperidone in the treatment of schizophrenia

作　　者：李强[1] 王崴[1] 陈策[1] 李雅妹[1] 

机构地区：[1]西安交通大学医学院第一附属医院,陕西西安710061

出　　处：《华西药学杂志》2007年第3期354-355,共2页West China Journal of Pharmaceutical Sciences

摘　　要：目的比较思瑞康(进口喹硫平)和维思通治疗精神分裂症的疗效及安全性。方法将68例符合CCMD-3的精神分裂症患者随机分为两组,分别给予思瑞康与维思通治疗42 d。采用阳性症状与阴性症状量表(PANSS)评定疗效,不良反应症状量表(TESS)评定不良反应。结果两组患者经42 d治疗后,其有效率分别为85.3%和88.2%,两药疗效的差异无显著性(P>0.05)。思瑞康组的不良反应发生率低于维思通组,但差异无显著性(P>0.05)。维思通组锥体外系反应和内分泌改变的发生率均明显高于思瑞康组(35.3%/8.8%;14.7%/0,P<0.05)。维思通组的体重增加较思瑞康组明显(P<0.05),但两药引起的不良反应均为轻度或中度,患者耐受性较好。结论两种药物对治疗精神分裂症均有确切疗效,且安全性高,思瑞康的不良作用较小。OBJECTIVE To compare the efficacy and safety of Seroquel and Resperidone in the treatment of schizophrenia. METHODS 68 patients with schizophrenia by CCMD - 3 were randomly divided into two groups treated with Seroquel or Risperldone for 6 weeks. The positive and negative syndrom scale（ PANSS ） and treatment emergent symptoms scale （TESS） were used to evaluate effects and adverse reaction before and at the ends of 2,4,6 weeks of treatment. RESULTS The total effective rates of Seroquel and Resperidone groups were 85.3% and 88.2%, respectively after 6 weeks. There was no significant difference between the two groups （ P 〉 0.05 ）. Incidence of adverse effects was lower in Seroguer group, but there was not the significant difference （ P 〉 0.05 ）. The rates of extrapyramidal symptoms and endocrine change were significantly higher in Resperidone group than those in Seroquel group （35.3%/ 8.8%;14.7%/0.0% ,P 〈 0.05 ）. Weight gain was significantly higher in Resperidone group than those in Seroquel group （P 〈 0. 05 ）. But these side effects were not serious, and patients often had good tolerability for them. CONCLUSION The results suggested that Seroquel was as effective as Resperidone for the treatment of schizophrenia, but two agents had different side effects profile.

关 键 词：思瑞康 维思通 精神分裂症 疗效 安全性 

分 类 号：R969[医药卫生—药理学]